GFAP and depressive symptom measurement: Disruption of the BBB allows pro-inflammatory molecules to invade the central nervous system (CNS), activate microglia, and drive neuroinflammation, inducing or exacerbating depression, which may be manifested as a sustained elevation of glial fibrillary acidic protein (GFAP) levels [122].